Treatment of knee articular cartilage defects: surgical strategies, results and analysis of factors determining the clinical outcome

Articular cartilage lesions, with their inherent limited healing potential, are hard to treat and remain a challenging problem for orthopedic surgeons. Despite the development of several treatment strategies, the real potential of each procedure in terms of clinical benefit and effects on the joint degeneration processes is not clear. Aim of this PhD project was to evaluate the results, both in terms of clinical and imaging improvement, of new promising procedures developed to address the challenging cartilage pathology. Several studies have been followed in parallel and completed over the 3-year PhD, and are reported in detail in the following pages. In particular, the studies have been focused on the evaluation of the treatment indications of a scaffold based autologous chondrocyte implantation procedure, documenting its results for the classic indication of focal traumatic lesions, as well as its use for the treatment of more challenging patients, older, with degenerative lesions, or even as salvage procedure for more advanced stages of articular degeneration. The second field of study involved the analysis of the results obtained treating lesions of the articular surface with a new biomimetic osteochondral scaffold, which showed promise for the treatment of defects where the entire osteochondral unit is involved. Finally, a new minimally invasive procedure based on the use of growth factors derived from autologous platelets has been explored, showing results and underlining indicatios for the treatment of cartilage lesions and different stages of joint degeneration. These studies shed some light on the potential of the evaluated procedures, underlining good results as well as limits, they give some indications on the most appropriate candidates for their application, and document the current knowledge on cartilage treatment procedures suggesting the limitations that need to be addressed by future studies to improve the management of cartilage lesions.

The "Orthoplastic" combined surgical approach to open tibia fractures: a multicentric prospective outcome study

Introduction: Open fractures of the leg represent a severe trauma. The combined approach, shared between plastic and orthopaedic surgeons, is considered to be important, although this multidisciplinary treatment is not routinely performed. Aim of this study was to verify whether the orthoplastic treatment is of any advantage over the traditional simply orthopedic treatment, through a multicentric inclusion of these unfrequent injuries into a prospective study. Material and methods: The following trauma centres were involved: Rizzoli Orthopaedic Institute/University of Bologna (leading centre) and Maggiore Hospital (Bologna, Italy), Frenchay Hospital (Bristol, United Kingdom), Jinnah Hospital (Lahore, Pakistan). All patients consecutively hospitalized in the mentioned centres between January 2012 and December 2013 due to tibial open fractures were included in the study and prospectively followed up to December 2014. Demographics and other clinical features were recorded, including the type of treatment (orthopaedic or orthoplastic). The considered outcome measures included duration of hospitalization, time for bone union and soft tissue closure, Enneking score at 3, 6 and 12 months, the incidence of osteomyelitis and other complications. Results: A total of 164 patients were included in the study. Out of them 68% were treated with an orthoplastic approach, whereas 32% received a purely orthopedic treatment. All considered outcome measures showed to be improved by the orthoplastic approach, compared to the orthopaedic one: time for soft tissue closure (2 versus 25 weeks), duration of hospital stay (22 versus 55 days), time for bone union (6 versus 8.5 months) , number of additional operations (0.6 versus 1.2) and functional recovery of the limb at 12 months (27 versus 19, Enneking’s score). All results were statistically significant. Conclusion: The combined orthoplastic approach to the treatment of open tibia fractures, in particular for high grade injuries (Gustilo 3B), is proven to improve the outcome of these severe injuries.

Antiepileptic drugs and pregnancy. Population based pharmaco-epidemiological study on prescription patterns, pregnancy outcome and foetal health

Aims of the study: To assess the prevalence of Antiepileptic Drug (AED) exposure in pregnant women with or without epilepsy and the comparative risk of terminations of pregnancy (TOPs), spontaneous abortions, stillbirth, major congenital malformations (MCMs) and foetal growth retardation (FGR) following intrauterine AED exposure in the Emilia Romagna region (RER), Northern Italy (4 million inhabitants). Methods: Data were obtained from official regional registries: Certificate of Delivery Assistance, Hospital Discharge Card, reimbursed prescription databases and Registry of Congenital Malformations. We identified all the deliveries, hospitalized abortions and MCMs occurred between January 2009 and December 2011. Results: We identified 145,243 pregnancies: 111,284 deliveries (112,845 live births and 279 stillbirths), 16408 spontaneous abortions and 17551 TOPs. Six hundred and eleven pregnancies (0.42% 95% Cl: 0.39-0.46) were exposed to AEDs. Twenty-one per cent of pregnancies ended in TOP in the AED group vs 12% in the non-exposed (OR:2.24; CI 1.41-3.56). The rate of spontaneous abortions and stillbirth was comparable in the two groups. Three hundred fifty-three babies (0.31%, 95% CI: 0.28-0.35) were exposed to AEDs during the first trimester. The rate of MCMs was 2.3% in the AED group (2.2% in babies exposed to monotherapy and 3.1% in babies exposed to polytherapy) vs 2.0% in the non-exposed. The risk of FGR was 12.7 % in the exposed group compared to 10% in the non-exposed. Discussion and Conclusion: The prevalence of AED exposure in pregnancy in the RER was 0.42%. The rate of MCMs in children exposed to AEDs in utero was almost superimposable to the one of the non-exposed, however polytherapy carried a slightly increased risk . The rate of TOPs was significantly higher in the exposed women. Further studies are needed to clarify whether this high rate reflects a higher rate of MCMs detected prenatally or other more elusive reasons.

Differenze di genere tra le caratteristiche cliniche e outcome dei pazienti con cancro ospedalizzati per COVID-19.

Obiettivo: Lo scopo principale di questo studio è analizzare lo sviluppo di complicanze cardiovascolari (CV) nei pazienti con neoplasia e malattia moderata-severa da COVID-19 e valutare differenze di genere per il rischio di mortalità intraospedaliera o di complicanze CV. Materiali e Metodi. Popolazione oggetto di studio. Pazienti inclusi nel registro ISACS-COVID 19 (ClinicalTrials.gov: NCT05188612), dati raccolti a partire da Febbraio 2020 a Luglio 2022. I pazienti arruolati sono stati reclutati da centri ospedalieri di cinque paesi: Italia, Croazia, Macedonia, Serbia e Romania. Le caratteristiche d’inclusione comprendono: età >18 anni, essere ospedalizzati e avere diagnosi certa d’infezione da SARS-CoV2. Gli endpoint analizzati sono stati: mortalità intraospedaliera e lo sviluppo di scompenso cardiaco acuto (SCA) nei pazienti con neoplasia. Risultati. La popolazione finale oggetto dello studio era di 4,014 pazienti ospedalizzati per malattia da COVID-19. Di questi circa l’8% risultava affetto da neoplasia. I pazienti con neoplasia risultavano essere più frequentemente donne (49% vs 40%, p=0.004), con un’età media più alta (68.3±12.95 vs 65.2±15.6, p<0.001) ma con profilo di rischio CV simile ai pazienti liberi da neoplasia. A seguito di analisi logistica di regressione multivariata, le donne non risultavano avere un incremento del rischio di mortalità intraospedaliera (OR 0.83;95%CI 0.66-2.45), mentre la presenza di tumore era significativamente associata ad incremento di mortalità (OR 1.68;95%CI 1.16-2.45). Restringendo le analisi di regressione logistica ai pazienti oncologici, le donne presentavano un incremento del rischio di sviluppo di SC acuto (OR3.07;95%CI 1.14 – 8.30) così come lo era la presenza di tumore al seno (OR 2.26; 95%CI 1.38 – 12.1). Conclusioni. La presenza di neoplasia rappresenta una condizione che incrementa il rischio di mortalità intraospedaliera nei pazienti ricoverati con COVID-19, mentre il genere femminile no. Le donne sembrano avere un rischio aumentato di sviluppo di SC acuto soprattutto se presentano un tumore al seno